Breaking news

America’s Race For Humanoid Robots: Can It Catch Up with China?

U.S. tech giants are betting big on humanoid robots, but analysts warn they’re already trailing China. With Nvidia’s Jensen Huang and Tesla’s Elon Musk fueling investor enthusiasm, the competition is heating up. Yet, China’s rapid progress mirrors its dominance in electric vehicles, positioning it ahead in this new frontier.

The Robotics Revolution

Humanoid robots—AI-driven machines designed to mimic human movement—are set to transform industries from manufacturing to customer service. The U.S. sees them as crucial to future economic growth, but analysts caution that China’s aggressive industrial policies and supply chain advantages give it a head start.

Nvidia’s Huang recently unveiled new tech for humanoid robotics, while Musk’s Tesla aims to produce 5,000 Optimus robots in 2024. That puts it ahead of U.S. rivals like Apptronik and Boston Dynamics, but not China’s Agibot, which has matched Tesla’s production target. Meanwhile, Unitree Robotics has already sold humanoid models directly to consumers.

Price & Scale: China’s Edge

Morgan Stanley estimates humanoid robot production costs range from $10,000 to $300,000. But China’s scale is driving prices down. Unitree’s G1 starts at $16,000, while Tesla’s Optimus Gen2 is projected at $20,000—if Tesla can optimize costs using Chinese components.

China isn’t just ahead on pricing. Over the past five years, it has filed 5,688 humanoid robot patents—compared to just 1,483 from the U.S. EV giants like BYD and Geely have already deployed Unitree’s robots in factories, while Beijing actively supports large-scale production.

The U.S. Challenge

A recent SemiAnalysis report warns that China’s humanoid robots are entirely independent of U.S. components, posing an “existential threat” to American industry. To compete, U.S. firms must strengthen domestic manufacturing and diversify supply chains.

Bank of America predicts humanoid robot adoption will soar, reaching 1 million annual sales by 2030 and 3 billion in operation by 2060. But for now, China leads. If the U.S. wants a stake in the future of robotics, time is running out.

Anthropic Acquires Coefficient Bio In $400 Million Stock Deal

Anthropic acquired biotech AI startup Coefficient Bio in a deal valued at approximately $400 million in stock, according to people familiar with the matter. Sources confirmed the transaction, although detailed financial terms were not publicly disclosed.

Deepening Forays Into Healthcare And Life Sciences

The acquisition follows Anthropic’s earlier launch of Claude for Life Sciences, a tool designed to support scientific research and drug discovery. The deal expands the company’s activity in healthcare and biotechnology. Anthropic is increasing its focus on applying AI models to scientific workflows, including data analysis and experimental design. Expansion into life sciences reflects broader industry trends.

Transforming Computational Drug Discovery

Coefficient Bio was founded eight months ago by Samuel Stanton and Nathan C. Frey, both former researchers at Genentech’s Prescient Design group. The company focused on applying AI to drug discovery and biological research processes. Its technology aims to improve efficiency in identifying drug candidates and analyzing biological data. Early-stage development reflects growing interest in AI-driven research tools.

Strategic Talent And Expertise Integration

Around 10 employees from Coefficient Bio will join Anthropic following the acquisition, strengthening its health and life sciences team. The group will contribute to the development of AI models for scientific and medical applications. Access to specialized talent supports the expansion of capabilities in drug discovery and biological research.

Industry Context And Outlook

Investment in AI for drug discovery has increased as companies seek to reduce development timelines and costs. Large technology firms and startups are expanding activity in this area. Further developments will depend on how effectively Anthropic integrates the team and advances its life sciences strategy.

eCredo
The Future Forbes Realty Global Properties
Uol
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter